Literature DB >> 28892924

Comparison of Pioglitazone and Metformin Efficacy against Glucocorticoid Induced Atherosclerosis and Hepatic Steatosis in Insulin Resistant Rats.

I M Nagendra Nayak1, Koyagura Narendar2, Patil Ashok M3, M G Jamadar4, V Hemanth Kumar2.   

Abstract

INTRODUCTION: Insulin Resistance is a major cause of Atherosclerosis (AS) and Non Alcoholic Fatty Liver Disease (NAFLD). These lipid alterations in blood vessels and liver may progress to cardiovascular abnormalities and cirrhosis respectively. Drugs like pioglitazone (PIO) and metformin (MET) are effective insulin sensitizers used in T2DM. But their efficacy and tolerability needs to be compared in IR associated abnormalities. AIM: To compare the efficacy of PIO and MET in glucocorticoid induced AS, Hepatic Steatosis (HS) and IR in albino rats.
MATERIALS AND METHODS: Male Wistar albino rats were randomized into four groups (n=6). Group 1 (Normal control) rats consumed 2% gum acacia orally for 12 days. Group 2 {dexamethasone (DEX) control} rats were administered 2% gum acacia orally for 12 days and DEX (8 mg/kg) intraperitoneally (i.p.) from 7th to 12th day during the study period. Group 3 and 4 (PIO and MET control) rats received oral administration of PIO (45 mg/kg) and MET (1000 mg/kg) for 12 days respectively. Both groups were treated with DEX (8 mg/kg/i.p.) from 7th to 12th day during the study period. On last day, fasting blood was collected and rats were sacrificed by cervical dislocation; aorta and liver tissues were isolated for the histopathological examination. Body weight, liver weight and liver volume were measured. Blood samples were processed for biochemical parameters. The data were analysed by One-way Analysis of variance (ANOVA) followed by Scheffe's multiple comparison post-hoc test. The statistical significance was assumed at p<0.05.
RESULTS: Our results established the possible role of DEX in the development of AS and HS. Histopathological examination of Group 2 rats treated with DEX showed a marked lipid accumulation in the aorta and liver. Administration of MET and PIO resulted in partial to complete restoration of DEX induced fatty changes in aorta and liver. Both drugs significantly (p<0.05) prevented the elevation of insulin, lipid, glucose levels, liver weight and liver volume in DEX treated rats. They had significantly (p<0.05) improved body weight and insulin sensitivity. However, PIO was highly significant (p<0.05) compared to MET in reducing DEX induced IR complications.
CONCLUSION: These findings suggest that PIO was more effective insulin sensitizer compared to MET in reducing AS, HS and IR induced by glucocorticoids.

Entities:  

Keywords:  Dexamethasone; Dyslipidemia; Fatty changes; Insulin sensitizers

Year:  2017        PMID: 28892924      PMCID: PMC5583870          DOI: 10.7860/JCDR/2017/28418.10193

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  44 in total

1.  Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study.

Authors:  G A Garinis; B Fruci; A Mazza; M De Siena; S Abenavoli; E Gulletta; V Ventura; M Greco; L Abenavoli; A Belfiore
Journal:  Int J Obes (Lond)       Date:  2010-02-23       Impact factor: 5.095

Review 2.  Hepatic triacylglycerol accumulation and insulin resistance.

Authors:  Cynthia A Nagle; Eric L Klett; Rosalind A Coleman
Journal:  J Lipid Res       Date:  2008-11-06       Impact factor: 5.922

Review 3.  Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment.

Authors:  Jessica L Hwang; Roy E Weiss
Journal:  Diabetes Metab Res Rev       Date:  2014-02       Impact factor: 4.876

4.  Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes.

Authors:  Fabrice M A C Martens; Frank L J Visseren; Eelco J P de Koning; Ton J Rabelink
Journal:  J Cardiovasc Pharmacol       Date:  2005-12       Impact factor: 3.105

5.  Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

Authors:  Imre Pavo; György Jermendy; Tamas T Varkonyi; Zsuzsa Kerenyi; Andras Gyimesi; Sergej Shoustov; Marina Shestakova; Matthias Herz; Don Johns; Belinda J Schluchter; Andreas Festa; Meng H Tan
Journal:  J Clin Endocrinol Metab       Date:  2003-04       Impact factor: 5.958

6.  Dexamethasone impairs insulin signalling and glucose transport by depletion of insulin receptor substrate-1, phosphatidylinositol 3-kinase and protein kinase B in primary cultured rat adipocytes.

Authors:  Jonas Burén; Hui-Xia Liu; Jørgen Jensen; Jan W Eriksson
Journal:  Eur J Endocrinol       Date:  2002-03       Impact factor: 6.664

7.  Hyperinsulinemia and related atherosclerotic risk factors in the population at cardiovascular risk: a community-based study.

Authors:  K L Chien; Y T Lee; F C Sung; H C Hsu; T C Su; R S Lin
Journal:  Clin Chem       Date:  1999-06       Impact factor: 8.327

8.  Maternal rat diabetes mellitus deleteriously affects insulin sensitivity and Beta-cell function in the offspring.

Authors:  Abdel-Baset M Aref; Osama M Ahmed; Lobna A Ali; Margit Semmler
Journal:  J Diabetes Res       Date:  2013-08-12       Impact factor: 4.011

Review 9.  Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.

Authors:  Paola Portillo-Sanchez; Kenneth Cusi
Journal:  Clin Diabetes Endocrinol       Date:  2016-04-12

Review 10.  Atherosclerosis: process, indicators, risk factors and new hopes.

Authors:  Mahmoud Rafieian-Kopaei; Mahbubeh Setorki; Monir Doudi; Azar Baradaran; Hamid Nasri
Journal:  Int J Prev Med       Date:  2014-08
View more
  1 in total

1.  Prevention of Elevation in Plasma Triacylglycerol with High-Dose Bezafibrate Treatment Abolishes Insulin Resistance and Attenuates Glucose Intolerance Induced by Short-Term Treatment with Dexamethasone in Rats.

Authors:  Maiara Destro Inácio; Alex Rafacho; Nathália Aparecida de Paula Camaforte; Poliana Teixeira; Priscilla Maria Ponce Vareda; Natália Moretti Violato; José Roberto Bosqueiro
Journal:  Int J Endocrinol       Date:  2018-11-08       Impact factor: 3.257

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.